High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Ignazio Majolino, Marco Ladetto, Anna Locasciulli, Daniela Drandi, Fabio Benedetti, Andrea Gallamini, Teodoro Chisesi, Angelo De Blasio, Mario Boccadoro, Corrado Tarella
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission'. Together they form a unique fingerprint.